AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology.
The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products.
It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines.
In addition, the company operates an online platform that sells ViraxClear and ViraxCare products.
It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions.
The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally.
The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021.
Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
Country | GB |
IPO Date | Jul 21, 2022 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 17 |
CEO | James Foster |
Contact Details
Address: 30 Broadwick Street London, GB | |
Website | https://viraxbiolabs.com |
Stock Details
Ticker Symbol | VRAX |
Exchange | NASDAQ |
Fiscal Year | April - March |
Reporting Currency | USD |
CIK Code | 0001885827 |
CUSIP Number | G9495L109 |
ISIN Number | KYG9495L1251 |
Employer ID | 00-0000000 |
SIC Code | 2835 |
Key Executives
Name | Position |
---|---|
James Foster | Chairman & Chief Executive Officer |
Dr. Nigel McCracken M.Sc., Ph.D. | Chief Operating Officer & Chief Technical Officer |
Jason D. Davis | Chief Financial Officer |
Clement Monteil | Head of Scientific Research & Development |
Joel Yeung | Accounting Manager |
Lily Fu | Head of Supply Chain |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 23, 2024 | 6-K | Filing |
Dec 17, 2024 | 6-K | Filing |
Dec 10, 2024 | 6-K | Filing |
Nov 20, 2024 | 6-K | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 31, 2024 | 6-K | Filing |
Oct 23, 2024 | 6-K | Filing |
Sep 30, 2024 | 6-K | Filing |
Sep 30, 2024 | 424B5 | Filing |
Aug 23, 2024 | 6-K | Filing |